323 results about "Central nervous system" patented technology

An improved method of treating cancers with engineered T cells is described.

The present disclosure provides double stranded oligonucleotides, compositions, and methods relating thereto. The present disclosure encompasses the recognition that structural elements of double stranded oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and / or internucleotidic linkages) or patterns thereof, and / or stereochemistry (e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages), and / or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, Ago2 loading, thermal stability, in vivo stability, delivery to tissues and into cells, etc. The present disclosure also provides methods for treatment of diseases, e.g., hepatic diseases, central nervous system (CNS) diseases, etc., using provided double stranded oligonucleotide compositions, for example, in RNA interference.

The disclosure provides methods for the for treatment of psychosis, such as schizophrenia, or depression (such as bipolar depression) and / or anxiety, comprising administering to a patient in need thereof, (i) a 5-HT2A or 5-HT2A / D2 receptor ligand, for example a substituted heterocycle fused gamma-carboline as described herein, in free, pharmaceutically acceptable salt or prodrug form, and (ii) a nitric oxide donor, separately (sequentially or simultaneously), or in combination (e.g., in a fixed dose combination).

The invention provides a cyclic peptide used for treating, improving or preventing nervous system injury of mammals or diseases or pains caused by the injury, neurodegenerative diseases, anxiety or epilepsy or used as a neuronal protective agent, a conjugate containing the cyclic peptide, a pharmaceutical composition containing the cyclic peptide or the conjugate and application of the cyclic peptide and the conjugate.

The invention relates to a phenylpropanoid compound as well as a preparation method and application thereof, in particular to a phenylpropanoid compound extracted from pleione bulbus pseudobulb as well as a preparation method and application thereof, and belongs to the technical field of medicines. The invention provides a method for preparing 10 new compounds from pleione bulbocodioides pseudobulb as a raw material for the first time, systematically evaluates the anti-neuroinflammation activity of pleione bulbocodioides pseudobulb, and clarifies the application of pleione bulbocodioides pseudobulb in development and treatment of central nervous system diseases. According to the invention, abnormally activated BV-2 microglial cells induced by LPS (Lipopolysaccharide) are adopted, and the NO release amount is taken as an index, so that the effect of the compound 1-10 on inhibiting excessive activation of the microglial cells is preliminarily evaluated. The result shows that the novel compounds 1-10 can inhibit the release of LPS-induced BV-2 microglial cell NO. Therefore, the compound prepared in the invention can be applied to development of drugs for treating central nervous system diseases.

The present disclosure relates to compounds of formula (I) that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and / or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and / or tissue hydration, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.

Provided herein are peptide amphiphiles (PAs) comprising a bioactive peptide, nanofibers displaying the bioactive PAs, and methods of use thereof. The disclosed peptide amphiphiles comprise a hydrophobic tail, a structural peptide segment, a charged peptide segment, and a bioactive IKVAV peptide. The disclosed PAs may be used in cell culture methods and in methods of treating central nervous system injury.

This invention provides a novel GABA structure with better efficacy, reduced side effects, and greater safety for clinical use. A This invention relates to receptor agonists, specifically a phenol derivative, its preparation method, and its use in the central nervous system. The phenol derivative provided by this invention offers more and better drug options for inducing or maintaining anesthesia in animals or humans, promoting sedation and hypnosis, and treating and / or preventing anxiety, nausea, vomiting, migraines, seizures, epilepsy, neurodegenerative diseases, and other central nervous system-related disorders.

The present invention relates to a polypeptide comprising the crystallizable fragment (Fc) region of IgG for use in the prevention or treatment of diseases, particularly diseases affecting the central nervous system. The polypeptide is administered locally to the affected compartment, particularly the central nervous system. The Fc region has a modification that reduces affinity for the neonatal Fc receptor (FcRn), resulting in increased brain to serum concentrations of the polypeptide.

An improved method of treating cancers with engineered T cells is described.

The invention relates to the technical field of exosome preparations, and particularly discloses an exosome nasal delivery preparation as well as a preparation method and application thereof. The preparation comprises the following components: 1 * 10 < 9 >-5 * 10 < 11 > particle number / ml of exosome, 1%-4% w / v of a saccharide protective agent, 0.5%-4.5% w / v of an alcohol protective agent, 0.05%-1% w / v of an absorption enhancer and a solvent. The exosome nasal delivery preparation can break through the blood brain barrier and quickly take effect, and the intracerebral delivery efficiency of the exosome nasal delivery preparation can be improved by 2-5 times compared with intravenous injection. The nasal administration preparation can be used for treating central nervous system diseases such as cerebral apoplexy and the like, and can remarkably improve the neurological function, reduce the cerebral infarction area and promote functional recovery.

The present invention relates to the use of recombinant porcine adeno-associated virus (AAV) vectors comprising peptide-modified porcine AAV serotype 1 (AAVpo1) capsids in the gene therapy of muscle and / or central nervous system (CNS) disorders, particularly neuromuscular diseases such as genetic neuromuscular diseases.

Provided are compositions and method for prophylaxis and / or therapy of hearing loss or related dysfunctions, including but not limited to tinnitus, that could be ameliorated by restoring central nervous system inhibitory synapses. The compositions include polynucleotides and viral vectors that are used to express at least one GABA receptor component which may be a GABAA receptor alpha 1 subunit or GABAR receptor Ib subunit. Expression of the GABA receptor may be under control of a CaMKII promoter.

This invention discloses a traditional Chinese medicine composition for improving fever in wind-heat common cold, belonging to the field of traditional Chinese medicine preparation technology. Addressing the shortcomings of existing Western medicines that suppress fever through central nervous system suppression, easily damaging organs and inhibiting microcirculation, and the limitations of traditional Chinese medicine preparations such as bitter and cold properties that astringe pathogens, causing low-grade fever rebound, damaging yin and spleen, and insufficient ability to resolve phlegm and strengthen the body, this invention innovatively combines the principles of monarch, minister, assistant, and guide herbs in a synergistic formulation based on the core microscopic pathogenesis of wind-heat common cold: "constriction of visceral microvessels, stagnation of heat pathogens, high fever depleting body fluids, fluid deficiency and blood stasis, and phlegm production due to stagnation." This invention is prepared using gardenia, platycodon, angelica, peppermint, ophiopogon, dandelion, lily, coix seed, and rehmannia as core raw materials. It utilizes pungent and dispersing herbs to open up the microcirculation of the body surface and lungs, dispersing stagnant heat and replacing the traditional bitter and cold heat-suppressing mechanism. Combined with heat-clearing and anti-inflammatory components, it targets and inhibits the release of inflammatory factors, resulting in stable fever reduction. Small doses of yin-nourishing herbs repair the damage to body fluids and blood caused by high fever, reversing the pathology of fluid deficiency and blood stasis. Spleen-strengthening and dampness-removing herbs harmonize the medicinal properties and strengthen the spleen. This invention achieves a balance of hot and cold properties, and addresses both tonification and purgation, providing a one-stop solution for complex symptoms such as fever, sore throat, nasal congestion, yellow phlegm, dry mouth, weakness, and fatigue caused by dampness in wind-heat colds. It provides stable fever reduction without rebound, and avoids the side effects of Western medicine and bitter and cold Chinese patent medicines. It addresses both the symptoms and the root cause, effectively avoiding post-cold sequelae and reducing the recurrence rate. Furthermore, the preparation process is simple, allowing for processing into various dosage forms, suitable for industrial mass production and widespread clinical application, possessing extremely high medical value and market potential.

The present invention relates to novel phosphate ester compounds of formula I for use in the treatment of central nervous system (CNS) diseases. Furthermore, the present invention provides an improved process for obtaining the compound of formula (I) in high yield and high purity. The novel phosphate ester compounds of formula-I are useful in the treatment of neurological, neuropsychiatric, metabolic and neurodevelopmental disorders.

The invention belongs to the technical field of medical monitoring and early warning, and relates to an electroencephalogram early warning system for central nervous adverse events in an acupuncture treatment course, and the system comprises an appliance integration and time synchronization association module which is used for synchronously generating an operation mark signal and a skin conductance signal; the reference state vector construction module and the safety stress vector construction module are respectively used for establishing an individualized physiological baseline vector and a safety stress limit vector; the real-time state vector generation module is used for generating a real-time physiological state vector; the dynamic weight adjusting module is used for generating a correction vector; the analysis and risk judgment module is used for analyzing whether the state evolution trajectory meets a risk condition or not; the grading early warning execution module and the intervention instruction triggering module are used for executing grading early warning and closed-loop physical intervention; the technical problems that in an existing acupuncture early warning method, operation and physiological signal time sequence correlation is weak, and multi-system collaborative risk evolution is difficult to comprehensively capture through single-dimension monitoring are solved.

This invention relates to a method for synchronous prediction of human thermal injury based on a dynamically coupled physiological model. First, a refined, segmented, multi-layered human physiological thermal model is constructed. Based on this model, a set of coupled biological heat transfer equations is established, embedding an active thermoregulation mechanism mediated by the human central nervous system. This set of equations is solved by deeply and dynamically coupling skin temperature, core temperature, and physiological parameters such as blood perfusion rate, metabolic rate, and sweat evaporation. Subsequently, by setting the initial and boundary conditions of a fire scene operation, the coupled equations are solved in one go using numerical methods. During the same solution process, the system synchronously and in parallel performs segmented skin burn risk assessment and overall human heat stress risk assessment. This invention overcomes the limitations of traditional models in segmented prediction and coupled active thermoregulation, achieving effective synchronous early warning of skin burn risk and overall heat stress risk in various parts of the human body under extreme thermal environments.

The present invention provides a C-terminal CDNF fragment sequence or a sequence which has at least 80% homology or sequence identity to said sequence. The C-terminal CDNF fragment protects ER stressed neurons, motoneurons and dopaminergic neurons and the fragment is capable of penetrating neuronal cell membrane as well as the blood-brain-barrier. The present invention further provides said fragment and pharmaceutical compositions comprising said fragment for use in treatments of degenerative diseases and disorders including central nervous system diseases, diabetes and retinal disorders. The present invention is also providing a C-terminal MANF fragment sequence or a sequence which has at least 80% homology or sequence identity to the said sequence and pharmaceutical compositions comprising said MANF fragment for use in the treatment of degenerative diseases and disorders including central nervous system diseases, diabetes and retinal disorders.

The scheme provides a kind of engineered exosome double drug delivery system loaded with ergosterol and its preparation method and application, belongs to the field of nanomaterials and nanobiomedicine, based on the innovative ROS-responsive nanomaterial CHPG design, load the active ingredient ergosterol to play the role of treatment and repair, which realizes the blood-brain barrier penetration and precise drug release in lesion area through targeted functional modification;It is wrapped in the nasal mucosa-derived stem cell exosome to form a drug delivery system Exo@Erg-CHPG-M, which combines the natural biological characteristics of exosome and the precise targeting advantage of nanomicelle, significantly improves the drug delivery efficiency, in vitro and animal model verification show that, the system can improve the neurological impairment and brain tissue injury after ischemic stroke by synergistically regulating inflammation and neural repair pathways, the scheme provides a new technical scheme for the precise treatment of central nervous system diseases such as cerebral stroke.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The present invention relates to pharmaceutical compounds of Formula (I):as further described herein, and pharmaceutical compositions containing such compounds, as well as methods of using these compounds to modulate the activity of aryl hydrocarbon receptor (AhR) and to treat conditions comprising inflammation inside the intestinal tract and certain disorders of the central nervous system affected by the gut-brain axis, including IBD, ulcerative colitis, Crohn's disease, Huntington's disease, and multiple sclerosis.

A method of treating or preventing central nervous system cancer in a subject in need thereof is described. The method includes administering to the subject a therapeutically effective amount of myeloid cells modified to express interleukin-2. A population of genetically engineered myeloid cells (GEMys) comprising bone marrow derived myeloid cells that have been genetically modified to express interleukin-2 is also described.

Provided herein are CB1 ligand-containing compounds, methods of delivering said compounds, and methods of treating diseases, disorders, and symptoms (e.g., central nervous system diseases, disorders, and symptoms) in a subject using said compounds.

Provides *Parabacterium* strains, cultures, inoculants, and their applications. Specifically, provides a *Parabacterium* strain, which may be a strain with accession number GDMCC No: 62664 or 62665, or a strain with at least 96.74% identity to the strain's 16S rRNA and / or at least 87% average nucleotide identity to the strain's genome; the strain or products based on the strain have good preventive or therapeutic effects on tumors or cancers, metabolic diseases, inflammatory or autoimmune diseases, infectious diseases, and central nervous system diseases.

The present invention relates to a composition for preventing, ameliorating or treating central nervous system diseases, comprising a peptidomimetic compound (NIP001) containing hydrophilic arginine and a hydrophobic histidine derivative. In the present invention, the peptidomimetic compound comprising hydrophilic arginine and a hydrophobic histidine derivative was confirmed to effectively inhibit inflammatory responses in microglia and to have the effect of improving the cognitive function of mice with scopolamine-induced cognitive impairment, and thus can be used as a targeted therapeutic agent for central nervous system diseases.

This invention relates to the packaging and screening of viral vectors, particularly to the packaging and screening of AAV mutants, specifically an adeno-associated virus mutant that efficiently infects HT-22 cells. By constructing a peptide mutant library of AAV9, a new AAV9 mutant with seven inserted amino acids was obtained through screening and verification. This mutant can effectively infect HT-22 cells at an MOI of 1E+5, achieving a higher infection rate than the natural AAV9 serotype at MOI=1E+5. The AAV9-HT01 mutant obtained after screening showed the best effect, with a significantly higher infection positivity rate compared to the control AAV9 serotype under the same MOI conditions. The fold increase was 4.4-fold as measured by luciferase (RLU) value detection. This effectively reduces the amount of AAV cells used for infection, saving experimental costs, and simultaneously makes it feasible to study the mechanisms of gene therapy for central nervous system diseases in HT-22 cells.

Methods for treating injuries to the central nervous system with a cilia activator are provided. The injury may be a traumatic brain injury (TBI). Related pharmaceutical compositions are provided.

The present invention relates to the field of therapy and drug delivery. More specifically, therapeutic methods and pharmaceutical compositions for treating disorders of blood-tissue barrier-protected organs that harbor substantial populations of postmittal neurons, such as organs derived from the neural tube, including the central nervous system and the eye. The disclosed methods and compositions involve topical administration of an effector component that targets intracellular biological targets to such organs, in combination with a saponin component that enhances the effective uptake of the effector component into cells and / or enhances the effective delivery of the effector component within cells where the biological target is present. For example, the effector component may be an oligonucleotide therapeutic that targets gene products associated with CNS and / or ocular disorders. Due to the cellular uptake stimulating and / or endosomal escape enhancing effects of the saponin component, the neuropharmaceuticals and ophthalmic compositions presented herein for topical administration to the CNS and / or eye, respectively, can be formulated with lower concentrations of the effector component and / or lower volumes, which provides safety benefits to neurons and patient comfort.